<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although evidence of <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mp ids='MP_0002899'>fatigue</z:mp> has been noted in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> survivors, whether <z:mp ids='MP_0001845'>inflammation</z:mp> is linked to the expression of <z:mp ids='MP_0002899'>fatigue</z:mp> and other symptoms arising from concurrent <z:e sem="disease" ids="C1559154" disease_type="Disease or Syndrome" abbrv="">chemoradiation</z:e> therapy (CXRT) has not been well studied </plain></SENT>
<SENT sid="1" pm="."><plain>Patients undergoing CXRT for locally advanced colorectal or <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> (n=103) reported multiple symptoms weekly via the M </plain></SENT>
<SENT sid="2" pm="."><plain>D </plain></SENT>
<SENT sid="3" pm="."><plain>Anderson Symptom Inventory (MDASI) from start of therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Serum samples were collected weekly to examine changes in inflammatory markers (interleukin (IL)-6, IL-8, IL-10, IL-1 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> (IL-1RA), vascular endothelial growth factor (VEGF), and soluble receptor 1 for <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (sTNF-R1)) via enzyme-linked immunosorbent assay </plain></SENT>
<SENT sid="5" pm="."><plain>Relationships between symptom severity and inflammatory-marker concentration levels were estimated using mixed-effect regression analysis, controlled for week of therapy, age, sex, body mass index, pre-CXRT <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> stage, pre-CXRT chemotherapy, pre-CXRT <z:chebi fb="0" ids="35664">statin</z:chebi> use, and type of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:mp ids='MP_0002899'>Fatigue</z:mp> was the most severe symptom over time, its development profile shared with pain, distress, <z:hpo ids='HP_0002329'>drowsiness</z:hpo>, <z:hpo ids='HP_0004396'>poor appetite</z:hpo>, and <z:e sem="disease" ids="C0037317" disease_type="Disease or Syndrome" abbrv="">disturbed sleep</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>sTNF-R1 and IL-6 shared a similar pattern of symptom development, with significant increase during CXRT and decrease after completion of CXRT </plain></SENT>
<SENT sid="8" pm="."><plain>Serum concentrations of sTNF-R1 were positively associated over time with the severity of <z:mp ids='MP_0002899'>fatigue</z:mp> (p=0.00097), while sTNF-R1 and IL-6 were positively related to the severity of a component score of the six most severe symptoms (both p&lt;0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>This longitudinal study suggests a role for over-expressed sTNF-R1 and IL-6 in the development of <z:mp ids='MP_0002899'>fatigue</z:mp> and other severe sickness symptoms during CXRT in patients with colorectal or <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> </plain></SENT>
</text></document>